Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZ


Primary Symbol: T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Comment by prophetoffactzon Jul 19, 2024 4:16pm
141 Views
Post# 36140611

RE:Quick question

RE:Quick question
jrsloan60 wrote: Why does it seem nobody wants the shares. Trades a hundred shares a day. Did our CEO get the market angry at him?


Money wants to see a proof of principle.

The Phase I/IIa clinical trial will provide safety/tolerability and preliminary efficacy data for the avenanthramide pill. Until you know it is safe/well tolerated and there are indications of preliminary efficacy it is very risky. 

PGX has only been proven in a 10L pilot facility that you can't make any money from. By the end of the year it could be scaled 5X and 10X. The 5X facilty will allow small-scale commercial production and the 10X facility is the decision point for mass industrialization. A partnership could then be signed validating the technology.  

Other programs are also before key proof of principle. Until there is a proof of principle we are early. It is not clear what we have or when. The diagnostic test while approved for adults has had a difficult launch. The coming pediatric data and deal will help clarify. 
<< Previous
Bullboard Posts
Next >>